We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Influence of G-CSF and EPO on Associative Learning and Motor Skills

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00298597
First Posted: March 2, 2006
Last Update Posted: April 23, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University Hospital Muenster
  Purpose
In the study we want to prove whether the subcutaneous application of granulocyte-stimulating factor (G-CSF) and erythropoetin (EPO) influence associative learning and/or motor skills of patients, who suffer from chronic stroke or amyotrophic lateral sclerosis. The study hypothesis is that G-CSF and EPO improve associative learning and/or motor skills.

Condition Intervention Phase
Chronic Stroke Amyotrophic Lateral Sclerosis Drug: granulocyte - colony stimulating factor (G-CSF) Drug: erythropoetin (EPO) Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Influence of G-CSF and EPO on Associative Learning and Motor Skills

Resource links provided by NLM:


Further study details as provided by University Hospital Muenster:

Primary Outcome Measures:
  • Learning success in a word learning model
  • Response time in motor function tests

Secondary Outcome Measures:
  • Response time in a word learning model
  • Total time and number of keystrokes in motor function tests

Estimated Enrollment: 180
Study Start Date: March 2006
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of chronic stroke or amyotrophic lateral sclerosis

Exclusion Criteria:

  • leucocytes > 10000/µl
  • hematocrit > 48%
  • thrombocytes < 150000/µl
  • severe rheumatoid arthritis
  • severe infection
  • severe liver or renal failure
  • severe arterial hypertension
  • recurrent thromboembolic events
  • severe coronary heart disease
  • myocardial infarction
  • malignant tumor
  • leukemia
  • peripheral arterial occlusion disease
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00298597


Locations
Germany
Department of neurology, University Hospital of Muenster
Muenster, Nordrhein-Westfalen, Germany, D-48149
Sponsors and Collaborators
University Hospital Muenster
Investigators
Principal Investigator: Wolf Rüdiger Schäbitz, MD Department of Neurology, University Hospital of Muenster, Germany
  More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00298597     History of Changes
Other Study ID Numbers: GCSFEPO_01
EudraCT Number 2005-001113-18
First Submitted: March 1, 2006
First Posted: March 2, 2006
Last Update Posted: April 23, 2009
Last Verified: April 2007

Additional relevant MeSH terms:
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases
Epoetin Alfa
Hematinics